Herbal Monograph
Wormwood
Artemisia absinthium L.
Asteraceae (Compositae)
Supreme bitter tonic for appetite, digestion, and bile flow -- the legendary herb of absinthe
Overview
Plant Description
Artemisia absinthium is an aromatic, herbaceous perennial plant growing 60-120 cm (2-4 feet) tall, occasionally reaching 150 cm under favorable conditions. The plant is characterized by its distinctive silvery-grey appearance, created by a dense covering of fine, silky, appressed trichomes (T-shaped hairs) on all aerial parts. The stems are erect, grooved, branching, and woody at the base, becoming herbaceous above. Leaves are alternate, 2-3 times pinnately divided (bipinnate to tripinnate) with obtuse, lanceolate segments; basal leaves are long-petiolate and up to 25 cm long, while upper leaves become progressively smaller and less divided. The leaves have a characteristic grey-green to silver color on both surfaces due to dense pubescence, and emit a powerfully aromatic, distinctly bitter-sharp scent when crushed. The inflorescence is a loose, leafy panicle bearing numerous small, nodding, hemispherical capitula (flower heads) approximately 3-5 mm in diameter. Each capitulum contains tubular, yellow florets (no ray florets) surrounded by grey-hairy involucral bracts. Flowering occurs from July to September in the Northern Hemisphere. The fruit is a tiny achene without a pappus. The root system consists of a strong, woody taproot with rhizomatous spreading. The entire plant possesses an intensely aromatic odor -- unmistakably sharp, herbaceous, and camphorous -- and an extraordinarily bitter taste that persists even at extreme dilutions. The species epithet 'absinthium' derives from the Greek 'apsinthion' (undrinkable), a testament to its legendary bitterness.
Habitat
Artemisia absinthium is a ruderal and pioneer species that favors dry, well-drained, sandy or rocky soils in full sun to partial shade. It thrives in disturbed ground, roadsides, waste places, field margins, old walls, and rubble. It tolerates poor, alkaline, and moderately saline soils but does not compete well in dense vegetation or waterlogged conditions. The plant is drought-tolerant once established and winter-hardy to USDA Zone 4 (-30 degrees C). It is commonly found in waste places, along roadsides, on dry hillsides and slopes, in pastures (where it is avoided by grazing animals due to its extreme bitterness), along railway embankments, and in traditional herb gardens and monastery gardens where it has been cultivated for centuries.
Distribution
Native to temperate Eurasia, ranging from Western Europe through Central and Eastern Europe, across the Mediterranean region, Turkey, the Caucasus, Central Asia, and Siberia. The center of diversity lies in the Mediterranean and Central Asian steppe regions. Widely naturalized in North America (established as early as the colonial period, likely brought by European settlers for medicinal use), South America (particularly Argentina and Chile), southern Africa, Australia, and New Zealand. In North America, it is now established across the northern and central United States and southern Canada, particularly in the Great Plains states, intermountain West, and New England. It is classified as a noxious weed in some US states and Canadian provinces due to its vigorous colonization of disturbed rangeland. The species has a very long history of cultivation throughout Europe, having been grown in monastery gardens since at least the early medieval period and in cottage gardens and physic gardens for centuries.
Parts Used
Aerial parts (Herba Absinthii)
Preferred: Dried herb for infusion or tincture; dried powdered herb for capsules; cut herb for bitter formulations
The dried aerial parts (stems, leaves, and flowers) harvested during or just before flowering constitute the official pharmacopeial drug. The European Pharmacopoeia (Absinthii herba), German Commission E, and ESCOP monographs all specify the aerial parts. This is the part used in traditional Western herbalism, in pharmaceutical bitter preparations, and as the primary botanical in absinthe and vermouth production. The whole herb contains the full spectrum of active constituents: sesquiterpene lactones (absinthin, artabsin), volatile oil (including thujone), flavonoids, phenolic acids, and tannins. The extreme bitterness (bitterness value >= 10,000 European Pharmacopoeia) is the signature organoleptic quality indicator.
Leaves (Folium Absinthii)
Preferred: Dried leaves for infusion; fresh leaves for fresh juice or poultice
Leaves harvested before flowering may be used separately, particularly in traditional preparations and in bitter digestive formulas. The basal leaves are larger and more divided; upper stem leaves are smaller. Leaf material has a similar chemical profile to the whole flowering herb but may have slightly different volatile oil proportions. Some traditional recipes specify leaf-only preparations.
Essential oil (Oleum Absinthii)
Preferred: Essential oil for external/aromatherapy use only; NOT for internal use
Steam-distilled essential oil from the aerial parts. Contains concentrated volatile compounds including alpha-thujone, beta-thujone, chamazulene, sabinene, myrcene, trans-sabinyl acetate, and other terpenes. The essential oil is the most concentrated source of thujone and is therefore subject to the strictest safety considerations. NOT recommended for internal use due to high thujone concentration and neurotoxicity risk. External use only, and with extreme caution. The chamazulene content gives the oil a blue to dark green color (similar to German chamomile oil). The composition varies significantly depending on chemotype, geographic origin, and harvest timing.
Key Constituents
Sesquiterpene lactones (bitter principles)
The sesquiterpene lactones, particularly absinthin, are the pharmacological foundation of wormwood's principal action as a bitter tonic (amarum). The extreme bitterness triggers the 'bitter reflex' -- a coordinated neurohumoral response mediated by bitter taste receptors (T2Rs) expressed on the tongue, stomach, intestine, and bile ducts. This reflex cascade enhances the entire digestive process: increased salivation, gastric acid secretion, pepsin output, bile release, pancreatic enzyme production, and intestinal motility. This is the mechanistic basis for the Commission E and ESCOP approved indications of loss of appetite and dyspepsia. Additionally, sesquiterpene lactones as a class demonstrate broad anti-inflammatory, antimicrobial, and antiparasitic activities, which support the traditional vermifuge and antimicrobial uses. Absinthin's hepatoprotective activity (demonstrated in CCl4-induced liver injury models) supports the traditional use for liver complaints.
Volatile oil (essential oil, 0.2-1.5% of dried herb)
The volatile oil contributes to wormwood's aromatic bitterness, carminative action (relieving intestinal gas and spasm), and antimicrobial properties. Chamazulene provides significant anti-inflammatory activity. However, the thujone content of the volatile oil is the PRIMARY safety concern with wormwood use and the reason for strict dose limitations and duration restrictions. The essential oil should NOT be used internally due to concentrated thujone. In whole-herb preparations (infusions, tinctures), the thujone is present in much lower concentrations than in the pure essential oil, and traditional dose limitations further reduce thujone exposure to levels well below toxic thresholds. The marked chemotypic variation in thujone content means that the safety profile of wormwood products can vary dramatically depending on the source plant material -- this is a significant quality control consideration.
Flavonoids
Flavonoids contribute antioxidant, anti-inflammatory, and cytoprotective activities that complement the primary bitter tonic action. Eupatilin's gastroprotective properties may partially mitigate the gastric irritation potential of the intensely bitter preparations. The antioxidant activity of quercetin and related flavonoids supports hepatoprotective effects alongside the sesquiterpene lactones. Artemetin's antiparasitic activity may contribute to the traditional vermifuge use.
Phenolic acids and tannins
Phenolic acids and tannins provide antioxidant, mild astringent, and mucosal-protective activities. The tannin content is relevant to wormwood's traditional use as a gastrointestinal remedy, providing a degree of mucosal protection that moderates the stimulant effects of the intensely bitter lactones. The hepatoprotective activity of chlorogenic acid complements the hepatoprotective effects of absinthin.
Lignans and acetylenes
Minor constituent classes that make modest contributions to the overall pharmacological profile. The lignans may be relevant to understanding the traditional emmenagogue action, while the polyacetylenes add to the antimicrobial spectrum.
Carotenoids and other compounds
These constituents provide general nutritional and antioxidant value but are not considered primary therapeutic compounds. The indirect effect of enhanced mineral absorption through improved digestive function (stimulated by the bitter principles) may be a clinically relevant ancillary benefit in patients with poor nutrient assimilation.
Herbal Actions
Wormwood's defining and PRIMARY pharmacological action. It is universally regarded as one of the strongest -- if not THE strongest -- bitter herb in Western herbalism. The bitterness value of Herba Absinthii (>= 10,000 by European Pharmacopoeia method) is among the highest of any medicinal plant. The extreme bitterness is due primarily to the dimeric sesquiterpene lactone absinthin. Bitter stimulation of T2R (type 2 taste receptor) receptors on the tongue and throughout the gastrointestinal tract triggers the 'bitter reflex': coordinated neurohumoral stimulation of salivation, gastric acid and pepsin secretion, bile release, pancreatic enzyme output, and increased intestinal motility. This comprehensive digestive stimulation underlies the Commission E and ESCOP approved indications for loss of appetite and dyspepsia. The bitter tonic action is dose-dependent: small doses (sub-therapeutic bitterness threshold) stimulate and normalize digestive function; very large doses can cause nausea and vomiting due to overwhelming bitterness and gastric irritation. This principle -- small doses stimulate, large doses depress -- is a classical pharmacological observation central to wormwood's therapeutic use.
[1, 2, 3, 4]Wormwood is a significant stimulant of both bile production by the liver (choleretic) and bile release from the gallbladder (cholagogue). The bitter principles, particularly absinthin, stimulate cholecystokinin (CCK) release from duodenal I-cells via the bitter reflex, which in turn triggers gallbladder contraction and sphincter of Oddi relaxation. Additionally, wormwood constituents directly stimulate hepatocyte bile acid synthesis. This choleretic/cholagogue action is the basis for the Commission E indication of biliary dyskinesia and for the traditional use in liver and gallbladder complaints. The bile-stimulating action also supports fat digestion and absorption and contributes to the mild laxative effect observed with wormwood use.
[1, 2, 3]The very name 'wormwood' reflects centuries of traditional use as an intestinal vermifuge (anti-worm agent). The antiparasitic action is attributed to multiple constituent classes: thujone has direct anthelmintic toxicity (damaging the integument and neurological function of intestinal parasites), sesquiterpene lactones demonstrate broad antiparasitic activity, and the intensely bitter taste and volatile oil compounds create an inhospitable intestinal environment for parasites. In vitro studies have demonstrated activity against Ascaris lumbricoides (roundworm), Enterobius vermicularis (pinworm), and various protozoal organisms. Traditional use for intestinal parasites is extensively documented across European, Middle Eastern, and North African folk medicine traditions. However, modern clinical trial evidence specifically for A. absinthium as an anthelmintic is limited; the traditional use predates controlled clinical investigation.
[3, 4, 5]Traditional use for fever reduction has been documented since ancient Egyptian and Greek medicine. Before the discovery of quinine from cinchona bark in the 17th century, wormwood was one of the most widely used European herbs for febrile conditions. The antipyretic mechanism is not fully characterized but likely involves prostaglandin synthesis inhibition by sesquiterpene lactones and anti-inflammatory effects. The related species A. annua (source of artemisinin) is far more significant as an antipyretic/antimalarial in modern practice, but A. absinthium's historical role in fever management is well documented in the Hippocratic corpus, Dioscorides, and medieval European herbals.
[3, 10]Kills or inhibits the growth of microorganisms
The essential oil and aqueous/ethanolic extracts of A. absinthium demonstrate broad-spectrum antimicrobial activity in vitro. Thujone, chamazulene, and other volatile oil components show activity against gram-positive and gram-negative bacteria (including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa), various fungi (Candida albicans, Aspergillus species), and some viruses. Sesquiterpene lactones contribute additional antimicrobial effects. The clinical significance of these in vitro findings at the concentrations achievable with oral dosing of whole herb preparations is uncertain, but the antimicrobial action supports traditional use for gastrointestinal infections and contributes to the overall therapeutic profile.
[3, 5]Relieves intestinal gas and bloating
The volatile oil content provides carminative (gas-relieving) action by relaxing smooth muscle spasm in the gastrointestinal tract and promoting the expulsion of intestinal gas. This action complements the bitter tonic effect: while the bitter principles stimulate digestive secretion and motility, the carminative volatile oil modulates excessive spasm and flatulence. This combined bitter-carminative profile makes wormwood particularly suited to dyspeptic conditions characterized by both poor appetite and bloating/distension.
[2, 3]Stimulates or increases menstrual flow
Traditional use as an emmenagogue (stimulant of menstrual flow) is documented across European herbal traditions from antiquity through the modern period. The mechanism may involve uterine smooth muscle stimulation by thujone and other volatile oil components, or indirect effects via improved pelvic circulation. This action is the basis for the ABSOLUTE contraindication in pregnancy. The emmenagogue reputation was significant enough that wormwood was historically used (often dangerously) as an abortifacient in folk practice, though its efficacy and safety for this purpose are wholly unacceptable by modern standards.
[3, 5]Reduces inflammation
Multiple anti-inflammatory mechanisms have been identified: chamazulene inhibits leukotriene B4 synthesis and 5-lipoxygenase; absinthin inhibits NF-kB-mediated inflammatory gene transcription; quercetin and other flavonoids modulate COX-2 and pro-inflammatory cytokine production. The anti-inflammatory profile is particularly relevant to the therapeutic use in inflammatory bowel conditions, as demonstrated in the Omer et al. (2012) Crohn's disease pilot study where wormwood supplementation reduced TNF-alpha levels and clinical disease activity.
[3, 7]Protects the liver from damage
Hepatoprotective effects have been demonstrated in animal models, attributed primarily to absinthin and flavonoid constituents. In CCl4-induced liver injury models, wormwood extracts reduced elevated liver enzymes (ALT, AST) and hepatic lipid peroxidation while increasing antioxidant enzyme activity. The choleretic action supports healthy bile flow, preventing bile stasis and its hepatotoxic consequences. However, the hepatoprotective action is considered mild compared to dedicated liver herbs such as milk thistle (Silybum marianum) or schisandra (Schisandra chinensis). Paradoxically, excessive wormwood use (particularly the essential oil) can itself be hepatotoxic due to thujone -- this underscores the dose-critical nature of this herb.
[3, 5]Closely related to and mediated by the bitter tonic action. Wormwood is one of the most potent herbal appetite stimulants in the European materia medica. The bitter reflex stimulated by absinthin and related compounds enhances appetite through: vagal stimulation of gastric hunger signals, increased gastric acid and enzyme secretion preparing the stomach for food intake, and modulation of orexigenic neuropeptide signaling. This is the most clearly established therapeutic indication, approved by Commission E for 'loss of appetite' with a 'well-established use' evidence rating. It is particularly indicated in convalescence, chronic illness with anorexia, and in elderly patients with reduced appetite and digestive function.
[1, 2, 4]Therapeutic Indications
Digestive System
Loss of appetite (anorexia, inappetence)
The PRIMARY and best-established indication for wormwood. Approved by the German Commission E (1998) for 'loss of appetite' and classified by ESCOP as a 'well-established medicinal use.' The mechanism is the bitter reflex: stimulation of gustatory T2R bitter receptors triggers vagal afferent signaling that enhances appetite and prepares the digestive system for food intake. Wormwood is specifically indicated in: convalescent anorexia (loss of appetite after illness), elderly patients with reduced appetite and digestive output, anorexia associated with chronic disease or debility, and functional appetite loss not due to mechanical obstruction. It is one of the most effective single herbal appetite stimulants available. Traditional dosing is 10-20 minutes before meals, in small doses, as a bitter infusion or tincture.
[1, 2, 3, 4]Dyspepsia and biliary dyskinesia
Approved by Commission E for 'dyspeptic complaints' and 'biliary dyskinesia.' Wormwood addresses functional dyspepsia (non-ulcer dyspepsia) characterized by: postprandial fullness, early satiety, epigastric discomfort, bloating, flatulence, and nausea from insufficient digestive secretions. The combined bitter tonic and choleretic/cholagogue actions stimulate gastric acid, bile, and pancreatic enzyme output, improving overall digestive efficiency. Biliary dyskinesia (sluggish gallbladder function with inadequate bile release) responds to the cholagogue action. IMPORTANT: Wormwood is CONTRAINDICATED in active gastric or duodenal ulcer, as stimulation of gastric acid production would exacerbate ulceration.
[1, 2, 3]Intestinal parasites (helminths and protozoa)
One of the most ancient and widespread indications for wormwood, reflected in the very name of the plant ('wormwood' = 'worm-wood,' the wood/herb used against worms). Traditional use as a vermifuge is documented in the Ebers Papyrus (ca. 1550 BCE), Dioscorides (1st century CE), and continuously throughout European herbal medicine. Specific traditional applications include: Ascaris lumbricoides (roundworm), Enterobius vermicularis (pinworm/threadworm), and other intestinal helminths. The anthelmintic action is attributed to thujone (directly toxic to parasites), sesquiterpene lactones, and the inhospitable bitter environment created in the intestinal lumen. While in vitro studies support antiparasitic activity, rigorous modern clinical trials are limited. In contemporary practice, wormwood is often used as part of an antiparasitic protocol alongside other vermifuge herbs (black walnut hull, clove, garlic) rather than as a sole agent.
[3, 5, 9]Bloating, flatulence, and intestinal colic
The carminative action of the volatile oil, combined with the bile-stimulating and digestive-enhancing effects of the bitter principles, addresses bloating and gas effectively. Wormwood is indicated in flatulent dyspepsia where gas accumulation accompanies poor digestion. The aromatic volatile oil relaxes intestinal smooth muscle spasm while the bitter principles normalize motility and secretion. Krebs et al. (2010) demonstrated clinical improvement in IBS patients treated with a bitter herb combination containing wormwood.
[2, 3, 8]Hepatobiliary System
Bile insufficiency and sluggish liver function
Wormwood's choleretic and cholagogue actions directly address insufficient bile production and sluggish bile flow. Indicated in functional biliary insufficiency presenting as: fat intolerance, pale stools (indicating reduced bile pigment), upper right quadrant discomfort, and general hepatic sluggishness. The choleretic action stimulates hepatocyte bile acid synthesis, while the cholagogue action promotes gallbladder contraction and bile duct flow. This combined hepatobiliary stimulation supports both fat digestion and hepatic detoxification pathways. Commission E specifically approves the indication of 'biliary dyskinesia.' CAUTION: Contraindicated in gallstone obstruction (cholelithiasis with obstruction) due to the risk of precipitating a biliary colic episode from stimulated gallbladder contraction against an impacted stone.
[1, 2, 3]Hepatoprotection and liver support (adjunctive)
Preclinical studies demonstrate hepatoprotective effects of wormwood extracts in animal models of chemically induced liver injury, mediated by absinthin's NF-kB inhibition, flavonoid antioxidant activity, and enhanced bile flow preventing cholestatic injury. The Omer et al. (2012) Crohn's disease study incidentally demonstrated reduced inflammatory markers including TNF-alpha, suggesting systemic anti-inflammatory and potentially hepatoprotective effects in humans. However, wormwood is not a primary hepatoprotective herb -- milk thistle (Silybum marianum), artichoke (Cynara scolymus), and schisandra (Schisandra chinensis) are preferred for this specific indication. Wormwood's hepatoprotective contribution is adjunctive and secondary to its primary bitter tonic role.
[3, 7]Immune System
Intestinal parasitic infections (traditional vermifuge)
Cross-referenced with digestive system indication. Wormwood's antiparasitic action can also be considered within the immune system framework, as effective helminth clearance depends on both direct anthelmintic toxicity and immune-mediated parasite expulsion (Th2-mediated eosinophilia and IgE responses). Traditional European herbalists recognized wormwood as a 'cleansing' herb that cleared the digestive tract of parasitic burden and restored healthy gut function. In contemporary integrative practice, wormwood is used in antiparasitic protocols often alongside supportive immune herbs.
[3, 5]Antimicrobial support (adjunctive, topical and internal)
The broad-spectrum antimicrobial activity of wormwood essential oil and extracts has been demonstrated in vitro against various bacterial, fungal, and protozoal organisms. Clinical relevance at achievable in vivo concentrations is not firmly established. In traditional practice, wormwood infusions were used for topical wound cleansing and as an antimicrobial gargle. Internal antimicrobial use is secondary to the primary bitter tonic indication.
[3]Musculoskeletal System
Topical anti-inflammatory (external use for joint and muscle pain)
Traditional external use of wormwood as a poultice, compress, or infused oil applied to painful joints and muscles. The anti-inflammatory volatile oil (particularly chamazulene) and counter-irritant properties provide localized pain relief. Historically used as a rubefacient (warming, reddening agent) applied over arthritic joints, bruises, and sprains. This external application avoids the systemic safety concerns associated with thujone ingestion.
[3, 5]Reproductive System
Amenorrhea and scanty menstruation (traditional emmenagogue)
Traditional use as an emmenagogue to promote menstrual flow in cases of amenorrhea or oligomenorrhea. The mechanism is not fully characterized but may involve uterine smooth muscle stimulation by volatile oil components. This is a well-documented traditional indication across European herbalism from antiquity. CRITICAL SAFETY NOTE: This emmenagogue action is the basis for the ABSOLUTE contraindication in pregnancy. Wormwood should never be used in pregnancy or suspected pregnancy. The traditional emmenagogue use should be practiced with extreme caution and only by experienced practitioners, as excessive doses carry serious risks.
[3, 5]Nervous System
Febrile conditions (traditional antipyretic)
Historical use for fever reduction documented from ancient Egypt through medieval Europe, and continuing in some folk traditions. Before the introduction of cinchona bark (quinine) from the Americas in the 17th century, wormwood was one of the principal European antipyretic herbs. Hippocrates recommended wormwood for fever, and Dioscorides described its use in intermittent fevers. The antipyretic mechanism likely involves prostaglandin synthesis inhibition and anti-inflammatory effects. In modern practice, this indication has been largely superseded by more effective and safer antipyretics, and A. annua (sweet wormwood/artemisinin) is far more significant for malaria treatment. However, the historical role is notable.
[3, 10]gastrointestinal-inflammatory
Crohn's disease (adjunctive, steroid-sparing)
The SedaCrohn study (Omer et al. 2012) was a landmark pilot randomized controlled trial investigating wormwood (as a dried herb powder, 750 mg three times daily) as adjunctive therapy in Crohn's disease patients who were on stable maintenance doses of corticosteroids. Over 10 weeks, the wormwood group showed: (1) significant clinical improvement measured by CDAI (Crohn's Disease Activity Index) scores, with 65% achieving clinical remission (CDAI < 170); (2) successful steroid tapering and discontinuation in most patients while maintaining remission; (3) significant reduction in TNF-alpha levels; and (4) improved quality of life and mood scores. This study provided the first controlled clinical evidence that wormwood may have steroid-sparing effects in Crohn's disease, potentially through TNF-alpha-mediated anti-inflammatory mechanisms. However, this was a small pilot study (n=40) and requires replication in larger, multi-center trials before wormwood can be recommended as standard adjunctive therapy for Crohn's disease.
[7]Irritable bowel syndrome (IBS)
Krebs et al. (2010) conducted a clinical study investigating a herbal combination containing wormwood along with other bitter and carminative herbs for IBS symptoms. The study demonstrated significant improvement in IBS symptom severity scores compared to placebo, with reduced abdominal pain, bloating, and bowel habit disturbance. The combination approach makes it difficult to attribute effects solely to wormwood, but the findings are consistent with wormwood's combined bitter tonic and carminative actions addressing the multifactorial pathophysiology of IBS (dysmotility, visceral hypersensitivity, and altered secretion).
[8]Energetics
Temperature
warm
Moisture
dry
Taste
Tissue States
cold/depression, damp/stagnation, damp/relaxation
In Western herbal energetics, wormwood is classified as WARM and DRY -- a classic 'warming bitter aromatic.' The extreme bitterness is the dominant organoleptic quality and places wormwood firmly among the 'simple bitters' (amara simplicia) and 'aromatic bitters' (amara aromatica) in the traditional classification of bitter herbs. The warmth derives from the volatile oil content, which adds pungent, diffusive qualities to the bitter action. Wormwood is specifically indicated for COLD, DAMP tissue states: poor appetite with cold, sluggish digestion; boggy, pale mucous membranes; weak, underactive hepatobiliary function; intestinal stagnation with bloating; and conditions associated with cold/depression and damp/relaxation (atonic, hypofunctioning gastrointestinal states). It is CONTRAINDICATED in hot, dry, irritated tissue states: active gastric or duodenal ulcer, inflammatory gastritis with burning pain, dry/atrophic mucous membranes, and constitutional patterns dominated by heat and dryness. The warming, drying quality means it should be used cautiously in patients who already tend toward dryness and heat. In traditional Galenic humoral medicine, wormwood was classified as hot in the first degree and dry in the second degree -- suitable for correcting cold, wet humoral imbalances. CAVEAT: Herbal energetics are interpretive frameworks within Western herbalism and are not standardized across all practitioners.
Traditional Uses
Ancient Egyptian medicine (Ebers Papyrus, ca. 1550 BCE)
- One of the earliest documented medicinal uses of wormwood in any civilization
- Used as an anthelmintic (worm expeller) for intestinal parasites
- Applied as a poultice for wounds and inflammations
- Used in fumigations and incense for ritual purification
- Employed as an insecticide and insect repellent
"The Ebers Papyrus (ca. 1550 BCE), one of the oldest and most complete surviving medical texts from ancient Egypt, contains references to 'sam' (Artemisia absinthium or a closely related Artemisia species) used for intestinal worms, as a wound dressing, and in various compound preparations. The Egyptians recognized the plant's bitter and aromatic properties and exploited them for both medicinal and practical (insecticidal) purposes. Wormwood's role in ancient Egyptian medicine establishes it as one of the oldest continuously used medicinal plants in the Western herbal tradition, with at least 3,500 years of documented therapeutic application."
[9]
Classical Greek and Roman medicine (Hippocrates, Dioscorides, Galen, Pliny)
- Hippocrates (ca. 460-370 BCE): recommended wormwood for jaundice, rheumatism, menstrual pains, and as a fever remedy
- Dioscorides (1st century CE, De Materia Medica): described wormwood as a bitter tonic for stomach complaints, a diuretic, an anthelmintic for roundworms and tapeworms, and an emmenagogue; also recommended 'wormwood wine' (vinum absinthiatum, wine infused with wormwood) for digestive complaints
- Galen (2nd century CE): classified wormwood as warm in the first degree and dry in the second; used it for hepatic and splenic disorders, digestive weakness, and to expel intestinal worms
- Pliny the Elder (Natural History): documented wormwood used for stomach disorders, tapeworms, and as an antidote against poisonous mushrooms and hemlock; noted that racehorses were given wormwood-infused water before competitions
"Dioscorides in De Materia Medica (ca. 70 CE) wrote of absinthion: 'It has a warming, binding action. It is good for the stomach when drunk, being diuretic. It is applied to the stomach and to the abdomen against distension and griping. Drunk with spikenard and seseli it helps those with a swollen stomach. It drives out worms from the intestines taken as a drink with water... A decoction of it applied to painful joints helps them. Its juice mixed with honey and Egyptian alum removes bruises around the eyes.' The Greek and Roman tradition established wormwood's core therapeutic identity as a digestive bitter, vermifuge, and emmenagogue that has persisted essentially unchanged for over two millennia."
Medieval European monastic and folk medicine (6th-15th century)
- Cultivated in monastery physic gardens throughout medieval Europe (Benedictine, Cistercian, Carthusian traditions)
- Hildegard von Bingen (12th century): recommended wormwood for digestive complaints, as a vermifuge, and as an external wash for wounds and skin conditions
- Used in 'plague vinegars' and 'Four Thieves Vinegar' during plague epidemics as a presumed disinfectant and prophylactic
- Employed in brewing as a bittering agent before the widespread use of hops (Humulus lupulus) -- the word 'grut' (continental European herbal ale) often included wormwood among its bitter botanicals
- Used as a strewing herb and insect repellent in dwellings (placed among linens and clothing to repel moths and fleas)
- Applied externally as a poultice or wash for wounds, bruises, and skin parasites
"In medieval monastic medicine, wormwood (Artemisia absinthium, known in Latin herbals as absinthium or absintheum) was a staple of the monastic pharmacy and physic garden. The Capitulare de Villis (ca. 795 CE), Charlemagne's decree on the management of royal estates, specifically mandated the cultivation of 'absintium' among other medicinal herbs. The 9th-century Plan of Saint Gall (an idealized monastic layout) included wormwood in the infirmary herb garden. Hildegard von Bingen (1098-1179) in Physica described wormwood as 'the most important master against all exhaustions' and recommended juice of wormwood cooked with honey and wine for digestive ailments. The medieval period also saw the development of wormwood-infused wines and liqueurs, precursors to the modern vermouth and absinthe traditions."
German Commission E and ESCOP (modern European phytotherapy)
- Commission E (1998) approved indication: loss of appetite and dyspeptic complaints
- ESCOP monograph: appetite loss, dyspepsia, biliary dyskinesia
- Official drug: Herba Absinthii (dried aerial parts)
- Specified as a short-term remedy: NOT to exceed 3-4 weeks of continuous use
- Strict thujone limits defined for all preparations
- Classified as well-established use based on extensive historical documentation and pharmacological evidence
"The German Commission E monograph (Bundesanzeiger, 1998) approved Artemisia absinthium (Herba Absinthii) for 'loss of appetite' and 'dyspeptic complaints.' The monograph specifies a daily dose of 2-3 g of the drug or equivalent preparations and notes that 'preparations should not be taken for longer than 3-4 weeks without consulting a physician.' Contraindications include pregnancy and gastric or duodenal ulcer. The ESCOP (European Scientific Cooperative on Phytotherapy) monograph likewise approves the indications of appetite loss, dyspepsia, and biliary dyskinesia, and provides evidence-based assessments of efficacy and safety."
British herbalism (16th century through present)
- Culpeper (1653, Complete Herbal): described wormwood as 'an herb of Mars' that strengthens the stomach, promotes appetite, aids digestion, kills worms, and promotes menstruation
- Gerard (1597, Herball): recommended wormwood for liver complaints, spleen disorders, dropsy, and as an insecticide
- Used extensively as a household remedy for worms in children, digestive complaints, and as a febrifuge
- Traditional wormwood beer and ale (before hops became dominant)
- Used in British folk medicine as an external wash for infected wounds and skin conditions
"Nicholas Culpeper in The Complete Herbal (1653) wrote: 'Wormwood is an herb of Mars... It is good for the inflammations of the eyes, taken inwardly with wine or Rhenish wine. It helpeth those that have the dropsy... It provokes the terms in women, being applied in a pessary... It is good against the biting of the shrew-mouse, and of the serpent. The oil of it takes away the pains of the sinews... It is a well-known bitter, cleansing the blood, opening obstructions of the liver and spleen.' The tradition of British herbalism consistently recognizes wormwood as a supreme bitter, digestive stimulant, and vermifuge, a characterization that has remained remarkably stable across five centuries of English-language herbals."
Russian and Eastern European bitter traditions
- Polyn (полынь) -- a deeply embedded folk remedy in Russian, Ukrainian, and Polish traditional medicine
- Used as a stomach bitter, appetite stimulant, and digestive tonic across Eastern Europe
- Wormwood vodka and wormwood liqueurs (traditional bitter spirits, precursors to commercial bitters)
- Employed in traditional Russian medicine for liver complaints, gallbladder dysfunction, and intestinal parasites
- Used as a bathing herb (added to banya/sauna water) for joint pain and muscular discomfort
- Employed in folk pest control: bundles of dried wormwood placed in grain stores, wardrobes, and animal bedding
"In Russian and Eastern European folk traditions, wormwood (polyn) occupies a central place as both a medicinal herb and a cultural symbol of bitterness. The herb is referenced extensively in Russian proverbs, poetry, and literature as a metaphor for life's bitter experiences. Medicinally, it was used as a stomach bitter (taken as a bitter tea or vodka infusion before meals), a vermifuge (particularly for children), and an external remedy for joint and skin conditions. The tradition of bitter herbal spirits (nastoykas) in Russia and Eastern Europe has deep roots, with wormwood being one of the principal bitter botanicals. The Eastern European folk medical tradition independently corroborates the Western European and Mediterranean indications for wormwood: digestive bitter, vermifuge, and hepatobiliary remedy."
[3]
The Absinthe tradition (cultural and historical context)
- Absinthe (the Green Fairy/La Fee Verte): the legendary spirit distilled with wormwood, anise, and fennel
- Originated in late 18th-century Switzerland (attributed to Dr. Pierre Ordinaire, ca. 1792, though this is disputed)
- Commercialized by Henri-Louis Pernod in Pontarlier, France, from 1805
- Became the drink of choice for Parisian bohemian culture in the late 19th century: consumed by Van Gogh, Toulouse-Lautrec, Degas, Verlaine, Rimbaud, Baudelaire, Oscar Wilde, and Hemingway
- Accused of causing 'absinthism' -- a syndrome of hallucinations, convulsions, psychosis, and madness -- attributed to thujone
- Banned in most of Europe and the United States between 1905-1915 (Switzerland 1908, France 1915, US 1912)
- Rehabilitated in the early 21st century (EU 1988, Switzerland 2005, US 2007) after modern research demonstrated that thujone levels in properly produced absinthe were far too low to cause neurotoxicity at normal consumption levels
- Modern consensus: 'absinthism' was almost certainly a combination of chronic alcoholism (absinthe was typically 55-72% ABV), methanol contamination from adulterated products, and general alcohol-related neurological damage rather than a specific thujone-mediated syndrome
"The absinthe saga is one of the most colorful chapters in the history of herbal medicine and toxicology. The spirit, distilled primarily from Artemisia absinthium with Pimpinella anisum (anise) and Foeniculum vulgare (fennel) as secondary botanicals, became emblematic of 19th-century Parisian artistic culture. At its peak in the 1880s-1900s, France consumed approximately 36 million liters of absinthe annually. The temperance movement and wine industry lobbied aggressively for its prohibition, citing 'absinthism' -- attributed to thujone -- as a unique and especially dangerous form of intoxication distinct from ordinary alcohol abuse. Modern analytical chemistry and pharmacological research, particularly the work of Lachenmeier et al. (2006, 2008) and Padosch et al. (2006), has convincingly demonstrated that: (1) historical absinthe contained far less thujone than previously assumed (typically 0-25 mg/L, not the hundreds of mg/L claimed); (2) at normal consumption levels, the thujone intake from absinthe was far below neurotoxic thresholds; (3) the symptoms of 'absinthism' are indistinguishable from chronic alcoholism; and (4) many cheap absinthes of the prohibition era were adulterated with toxic adulterants (copper salts for color, antimony compounds, methanol). The rehabilitation of absinthe in the 21st century represents a triumph of evidence-based toxicological assessment over decades of moral panic and flawed science."
[3]
Modern Research
Wormwood as steroid-sparing therapy in Crohn's disease (SedaCrohn study)
Landmark pilot randomized controlled trial investigating dried wormwood powder (Artemisia absinthium, 750 mg three times daily = 2250 mg/day total) as adjunctive therapy in patients with active Crohn's disease who were on stable maintenance doses of corticosteroids. Patients in the wormwood group underwent gradual steroid tapering while receiving wormwood; the control group underwent identical steroid tapering with placebo.
Findings: After 10 weeks of treatment: (1) 65% of patients in the wormwood group achieved clinical remission (CDAI < 170) compared to only 15% in the placebo group (P < 0.05). (2) The wormwood group achieved successful steroid tapering and discontinuation while maintaining remission, whereas placebo patients experienced disease flare upon steroid reduction. (3) TNF-alpha levels were significantly reduced in the wormwood group, suggesting an anti-inflammatory mechanism targeting this key pro-inflammatory cytokine in Crohn's disease pathogenesis. (4) Quality of life scores improved significantly in the wormwood group. (5) Mood and psychological well-being scores also improved. (6) No serious adverse events were attributed to wormwood. This study was groundbreaking as the first controlled clinical evidence for wormwood in inflammatory bowel disease and suggested a steroid-sparing potential that could have major clinical implications if confirmed in larger trials.
Limitations: Small sample size (n=40). Single-center. Pilot study design. Open-label steroid tapering component. Specific commercial preparation used (SedaCrohn brand); results may not generalize to other wormwood products. No long-term follow-up data. Has not yet been replicated in a larger, multi-center RCT. The mechanism of TNF-alpha reduction requires further characterization (is it absinthin, other sesquiterpene lactones, or the full phytochemical complex?).
[7]
Herbal bitter combination therapy for irritable bowel syndrome (IBS)
Clinical study investigating a standardized herbal combination containing Artemisia absinthium (wormwood) alongside other bitter and carminative herbs for the treatment of irritable bowel syndrome symptoms.
Findings: The herbal combination containing wormwood demonstrated significant improvement in IBS symptom severity scores compared to placebo. Patients reported reduced abdominal pain, decreased bloating and distension, improved bowel habit regularity, and better overall quality of life. The combined bitter tonic and carminative actions of the herbal formula addressed multiple pathophysiological targets in IBS: normalized motility (bitter-stimulated coordinated peristalsis), reduced visceral gas accumulation (carminative volatile oils), and improved digestive secretion (bitter reflex stimulation of acid, bile, and enzymes).
Limitations: Multi-herb combination product -- cannot attribute effects solely to wormwood. Sample size and study duration were limited. Specific product formulation may not be commercially available or generalizable. IBS subtype-specific responses not fully characterized. The placebo response rate in IBS studies is characteristically high (30-40%), which complicates interpretation.
[8]
Thujone pharmacology, toxicology, and the absinthe rehabilitation
Comprehensive body of modern research re-evaluating the toxicology of thujone and the historical claims of 'absinthism,' leading to the rehabilitation and re-legalization of absinthe in the EU and US.
Findings: Key findings from the aggregate modern research: (1) Thujone acts as a non-competitive antagonist at the GABA-A receptor, specifically at the picrotoxin binding site, blocking chloride ion conductance. This GABA-antagonistic mechanism explains the convulsant activity at high doses. (2) The LD50 of alpha-thujone in rats is approximately 45 mg/kg orally, and the convulsant threshold is approximately 30-40 mg/kg. (3) Analysis of historical and modern absinthe products by GC-MS consistently shows thujone levels of 0-25 mg/L (median approximately 9 mg/L), far lower than the hundreds of mg/L claimed in 19th-century prohibition-era literature. (4) At typical absinthe consumption levels, the daily thujone intake would be approximately 3-9 mg -- well below the convulsant threshold. (5) Chronic low-dose thujone exposure studies in animals have not demonstrated the cumulative neurotoxicity claimed for 'absinthism.' (6) The symptoms historically attributed to absinthism (tremor, hallucinations, seizures, psychosis) are consistent with severe chronic alcoholism and/or methanol/adulterant toxicity rather than a specific thujone-mediated syndrome. (7) The EU established maximum thujone limits for food and beverages (0.5-35 mg/kg depending on product category) based on comprehensive risk assessment, and absinthe was re-legalized under these regulations.
Limitations: Much of the historical analysis depends on reconstruction of 19th-century production methods and analytical chemistry not available at the time. Some uncertainty remains about the exact composition of the cheapest and most adulterated absinthes of the prohibition era. Animal toxicology studies using pure thujone may not perfectly model the effects of thujone within the full phytochemical matrix of whole wormwood preparations. Long-term human exposure studies at therapeutic herb doses are lacking.
[]
GABA-A receptor antagonism by thujone: mechanism of neurotoxicity
Electrophysiological and pharmacological characterization of thujone's mechanism of action at GABA-A receptors, explaining its convulsant and neurotoxic properties.
Findings: Hold et al. (2000) demonstrated that alpha-thujone is a modulator of the GABA type A receptor, specifically acting as a non-competitive inhibitor at the picrotoxin/TBPS (t-butylbicyclophosphorothionate) binding site. Thujone blocks chloride ion flux through the GABA-A receptor channel, reducing inhibitory neurotransmission in the CNS. This mechanism is shared with other convulsant agents (picrotoxin, pentylenetetrazol) and directly explains thujone's ability to cause seizures at high doses. Alpha-thujone was found to be more potent than beta-thujone at GABA-A receptor inhibition. The study established the molecular pharmacological basis for thujone neurotoxicity and provided the framework for risk assessment of thujone-containing foods and beverages.
Limitations: In vitro electrophysiology study using recombinant GABA-A receptors. In vivo pharmacokinetics (absorption, distribution, hepatic metabolism of thujone) affect the actual CNS concentration achieved from oral dosing of wormwood preparations. Thujone undergoes extensive first-pass hepatic metabolism, which may significantly reduce CNS exposure from oral ingestion of whole herb preparations compared to parenteral administration of pure thujone.
[]
Antimicrobial and antiparasitic activity of Artemisia absinthium extracts
In vitro investigations of the antimicrobial and antiparasitic spectrum of wormwood essential oil and various solvent extracts, supporting traditional use as a vermifuge and antimicrobial herb.
Findings: Multiple in vitro studies have demonstrated: (1) Essential oil activity against Staphylococcus aureus (including MRSA), Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus niger, with MIC values in the range of 0.5-10 mg/mL depending on the organism and essential oil chemotype. (2) Antiprotozoal activity against Plasmodium falciparum (the malaria parasite), Giardia lamblia, Leishmania species, and Trypanosoma species, though the activity is generally weaker than that of A. annua (artemisinin). (3) Anthelmintic activity against Ascaris suum and Haemonchus contortus in vitro, supporting the traditional vermifuge use. (4) The antimicrobial activity is attributed to thujone, chamazulene, and other terpene components of the essential oil, as well as to sesquiterpene lactones in non-volatile fractions.
Limitations: In vitro activity does not necessarily translate to clinical efficacy. The concentrations showing activity in vitro may not be achievable at the site of infection through oral dosing of whole herb preparations. Clinical trials specifically testing wormwood as an antimicrobial or antiparasitic agent in human infections are lacking. Chemotypic variation in essential oil composition means that different wormwood sources may have different antimicrobial spectra.
Appetite stimulation and bitter taste receptor (T2R) pharmacology
Modern research elucidating the molecular mechanisms underlying the traditional bitter tonic (appetite-stimulating and digestive-enhancing) action of wormwood, centered on bitter taste receptor (T2R) signaling.
Findings: The bitter reflex triggered by absinthin and other bitter compounds in wormwood is now understood at the molecular level: (1) T2R (type 2 taste receptor) family members on gustatory epithelial cells detect bitter compounds and signal via gustducin (a G-protein) to stimulate afferent vagal neurons. (2) T2R receptors are also expressed extra-orally throughout the GI tract (stomach, intestine, bile duct, pancreas), where bitter compound detection directly triggers local secretory and motility responses independent of taste perception. (3) Bitter-stimulated vagal afferents coordinate the 'cephalic phase' of digestion: increased gastric acid, pepsin, and intrinsic factor secretion; enhanced gastric motility; stimulation of cholecystokinin (CCK) release triggering gallbladder contraction; and increased pancreatic enzyme output. (4) Absinthin, with its exceptionally high bitterness index, is an extremely potent activator of this entire signaling cascade. These findings provide a modern pharmacological validation of the traditional 'bitter tonic' concept that has been the cornerstone of wormwood's therapeutic use for millennia.
Limitations: While the T2R signaling mechanism is well characterized, direct clinical studies specifically measuring the dose-response relationship of wormwood's effect on gastric acid secretion, bile output, and appetite scores in humans are limited. Most T2R pharmacology studies use isolated cell systems or animal models. The interaction between different bitter compounds in a complex herb extract (polypharmacy) on T2R signaling is not fully understood.
Anti-inflammatory mechanisms: NF-kB inhibition and cytokine modulation
Investigation of the anti-inflammatory mechanisms of Artemisia absinthium constituents, with particular focus on NF-kB pathway inhibition and TNF-alpha reduction relevant to the Crohn's disease findings.
Findings: Preclinical studies have identified multiple anti-inflammatory mechanisms of wormwood constituents: (1) Absinthin inhibits NF-kB (nuclear factor kappa-B) nuclear translocation, reducing transcription of pro-inflammatory genes including TNF-alpha, IL-1beta, IL-6, COX-2, and iNOS. (2) Chamazulene inhibits leukotriene B4 synthesis by blocking 5-lipoxygenase. (3) Flavonoids (quercetin, artemetin, eupatilin) inhibit COX-2 and modulate MAPK signaling pathways. (4) The Omer et al. (2012) clinical study confirmed TNF-alpha reduction in Crohn's disease patients taking wormwood, providing human evidence for the anti-inflammatory mechanism observed in preclinical models. (5) The multi-target anti-inflammatory activity (NF-kB, 5-LOX, COX-2) may explain the broad-spectrum anti-inflammatory effect observed clinically, as it targets multiple nodes of the inflammatory cascade rather than a single enzyme.
Limitations: Most mechanistic data is from in vitro and animal models. The relative contributions of individual constituents versus the whole phytochemical complex to the overall anti-inflammatory effect are not fully delineated. The clinical evidence is limited to one small RCT in Crohn's disease. Larger clinical studies measuring inflammatory biomarkers in response to standardized wormwood preparations are needed.
Safety assessment and thujone risk evaluation in herbal preparations
Comprehensive toxicological risk assessment of thujone exposure from medicinal wormwood preparations compared to the established NOAEL (No Observed Adverse Effect Level) and regulatory limits.
Findings: Risk assessment analysis has demonstrated: (1) The thujone content of properly prepared wormwood infusions (2-3 g herb in 150 mL water) is typically 2-10 mg per cup, depending on the herb chemotype and infusion time. Only a fraction of thujone in the dried herb transfers to the aqueous infusion due to its limited water solubility. (2) At the Commission E-recommended dose (2-3 g herb per day as infusion), the daily thujone intake is estimated at 3-12 mg, within the EU acceptable daily intake of 5 mg/day when used short-term. (3) Tincture preparations (1:5, 45-60% ethanol) extract thujone more efficiently but are dosed in smaller volumes (1-3 mL), resulting in comparable or slightly higher thujone exposure per dose. (4) The NOAEL for thujone in 28-day animal studies is approximately 5 mg/kg/day. For a 70 kg human with a 100-fold safety factor, this translates to a human reference dose of approximately 3.5 mg/day -- consistent with the Commission E dose limitation and 3-4 week maximum duration recommendation. (5) The essential oil (concentrated thujone) should NEVER be taken internally, as even small volumes could deliver neurotoxic thujone doses.
Limitations: Thujone content varies dramatically by chemotype, origin, and processing -- standardization is challenging. Long-term human toxicity data at medicinal herb doses is lacking; the 3-4 week limitation is a precautionary measure. Individual variation in thujone metabolism (CYP-dependent) may affect susceptibility. The safety factor applied from animal NOAEL to human dose involves uncertainty.
Preparations & Dosage
Infusion (Tea)
Strength: 1-1.5 g dried herb per 150 mL water; approximately 1:100 to 1:150 herb-to-water ratio
Pour 150 mL (one cup) of boiling water over 1-1.5 g of dried, finely cut Herba Absinthii. Cover and steep for 10-15 minutes. Strain. The resulting infusion is intensely bitter with a characteristic aromatic, herbaceous taste. Do not sweeten if the therapeutic goal is appetite stimulation or digestive enhancement -- the bitter taste itself is essential to the therapeutic mechanism (bitter reflex activation requires perception of bitterness). If the bitterness is truly intolerable, a small amount of honey may be added, though this reduces efficacy for bitter-mediated indications. Drink 15-20 minutes BEFORE meals for appetite stimulation and digestive support.
1-1.5 g dried herb per cup (150 mL), up to 2-3 cups per day. Maximum daily dose: 2-3 g dried herb (Commission E).
1-3 times daily, 15-20 minutes before meals
NOT to exceed 3-4 weeks of continuous use without practitioner reassessment (Commission E recommendation). A rest period of at least 2 weeks between courses is advisable.
NOT recommended for children under 12 due to thujone content. For adolescents aged 12-18: half adult dose under practitioner guidance only.
Infusion is the traditional and most common preparation method for wormwood. The bitter principles (absinthin) and flavonoids are partially water-soluble and are extracted by hot water infusion. However, the volatile oil (containing thujone) is only partially extracted by water -- a significant portion is lost to evaporation during steeping unless the vessel is covered. This means that properly prepared infusions contain LESS thujone per dose than tinctures or essential oil preparations, contributing to a relatively safer thujone exposure profile. The intense bitterness is an inherent and therapeutically necessary quality -- patients should be counseled that the bitterness is the medicine. Starting with a weaker infusion (0.5 g) and gradually increasing allows patients to acclimate to the extreme bitter taste. In traditional European practice, wormwood tea was often combined with other herbs to moderate the bitterness: peppermint (Mentha piperita), fennel (Foeniculum vulgare), or anise (Pimpinella anisum) were common companions.
Tincture
Strength: 1:5, 45-60% ethanol (dried herb). Fresh plant: 1:3, 65% ethanol.
Standard maceration: finely cut dried herb in 45-60% ethanol at a 1:5 ratio (w/v). Macerate for 2-4 weeks with daily agitation. Press and filter. Alternatively, fresh plant tincture at 1:3 in 65% ethanol. The tincture should be a deep olive-green to brown-green color with an intensely bitter taste and aromatic aroma. Dose is measured in drops to milliliters. For the extremely bitter wormwood, tincture drops in a small amount of water (30-50 mL) taken before meals is a practical dosing method.
10-30 drops (0.5-1.5 mL) of 1:5 tincture three times daily, taken in water 15-20 minutes before meals. Some sources recommend starting as low as 3-5 drops and titrating upward. Maximum: approximately 3-4.5 mL per day of 1:5 tincture.
Three times daily, 15-20 minutes before meals
NOT to exceed 3-4 weeks of continuous use without practitioner reassessment. Rest period of 2 weeks between courses.
NOT recommended for children due to thujone content and alcohol base.
Tincture is an efficient preparation that extracts both the water-soluble bitter principles and the alcohol-soluble volatile oil compounds more completely than aqueous infusion. This means tinctures contain proportionally MORE thujone per gram of herb equivalent than infusions -- a safety consideration that warrants strict dose limitation. The advantage of tincture dosing is precision: drops can be carefully measured and titrated. The low volume per dose (drops to 1 mL) also makes the intense bitterness more manageable than consuming a full cup of bitter tea. IMPORTANT: Wormwood is a dose-critical herb where the therapeutic window is relatively narrow. Small doses (3-30 drops) stimulate and normalize digestive function. Larger doses can cause nausea, vomiting, and at extreme doses, thujone-mediated neurological effects. The traditional principle of 'minimum effective dose' is especially important with wormwood.
Fresh Juice / Expressed Juice
Strength: Expressed juice from fresh aerial parts; approximately 1:1 herb-to-juice yield
Fresh aerial parts (leaves and stems) harvested during the growing season are juiced using a hydraulic press or masticating juicer. The expressed juice is a dark green, highly aromatic liquid with extreme bitterness. Fresh juice is used immediately or preserved by mixing with an equal volume of ethanol. Traditionally, fresh juice was mixed with honey to create a more palatable preparation.
5-10 mL fresh juice, diluted in water, taken before meals. Preserved juice (with ethanol): 2-5 mL three times daily.
1-3 times daily before meals
Seasonal availability limits long-term use. When available, adhere to the same 3-4 week maximum duration.
NOT recommended for children.
Fresh juice was a valued preparation in traditional European herbalism, believed to retain the full 'vital force' of the fresh plant. It contains the complete constituent profile including heat-labile compounds and volatile oil components. Fresh juice is seasonal and perishable unless preserved. In contemporary practice, tincture has largely supplanted fresh juice for practical reasons. Historical references to fresh wormwood juice appear in Hildegard von Bingen and other medieval herbals.
[3]
wormwood-wine
Strength: 15-30 g dried herb per liter of wine (approximately 1:33 to 1:67)
Historical preparation: macerate 15-30 g of dried Herba Absinthii in 1 liter of white or red wine for 1-2 weeks. Strain and store in dark glass. Alternatively, briefly simmer the herb in wine for 15-20 minutes, then strain. This is the direct ancestor of commercial vermouth (the name 'vermouth' derives from the German 'Wermut' for wormwood). Small glass (30-50 mL) served before meals as an aperitif.
30-50 mL (one small glass) of wormwood wine before meals as an aperitif/digestive stimulant.
Once daily before the main meal, or twice daily (lunch and dinner)
Moderate use as an aperitif; adhere to general wormwood duration guidelines
NOT recommended.
Wormwood wine (vinum absinthiatum) is one of the oldest medicinal preparations of this herb, described by Dioscorides in the 1st century CE and continuously used through medieval and early modern European practice. It served as both medicine and aperitif -- the tradition of the pre-dinner bitter aperitif has its roots in medicinal wormwood wine. Commercial vermouth (first produced in Turin in the 18th century by Antonio Benedetto Carpano) evolved from this medicinal tradition. The wine extraction medium efficiently extracts both bitter principles and aromatic compounds. This preparation combines the therapeutic effects of wormwood with the mild digestive-stimulant properties of wine itself. Note: Absinthe is a distinct preparation -- a distilled spirit made with wormwood, anise, and fennel at very high proof (55-72% ABV), which is different from wormwood wine.
Capsule / Powder
Strength: 250-500 mg dried powdered herb per capsule. Total daily dose 1.5-3 g.
Dried, finely powdered Herba Absinthii filled into vegetarian or gelatin capsules, typically 250-500 mg per capsule. This bypasses the extreme bitterness, which is advantageous for patient compliance but potentially reduces efficacy for appetite stimulation (since the bitter reflex requires taste perception). Some practitioners advocate opening capsules into water to ensure bitter taste perception when appetite stimulation is the primary goal.
500-750 mg (1-3 capsules of 250 mg) three times daily before meals. Maximum: 2-3 g per day. The SedaCrohn study used 750 mg three times daily (2250 mg/day total).
Three times daily before meals
NOT to exceed 3-4 weeks without practitioner reassessment
NOT recommended for children under 12.
Capsule form is the preparation used in the landmark SedaCrohn study (Omer et al. 2012) for Crohn's disease. The encapsulation bypasses the tongue but the bitter compounds still activate T2R receptors in the stomach and intestine (which express the same bitter taste receptors), potentially providing some of the digestive benefits even without oral bitter taste perception. However, for appetite stimulation specifically, the oral perception of bitterness is considered important for triggering the cephalic phase of digestion, and some practitioners argue that capsules are suboptimal for this indication. Capsule form is preferred when the anti-inflammatory or antiparasitic actions are the primary therapeutic goals, or when the patient cannot tolerate the extreme bitterness of tea or tincture.
external-compress
Strength: 3-5 g dried herb per 150 mL water for external compress (stronger than internal infusion)
Prepare a strong infusion (3-5 g dried herb per 150 mL boiling water, steeped 15 minutes). Soak a clean cloth in the warm (not hot) infusion and apply to the affected area as a compress. Alternatively, bruised fresh leaves can be applied directly as a poultice. The volatile oil provides counter-irritant, anti-inflammatory, and mild analgesic effects through topical application.
Apply warm compress to affected area for 15-30 minutes, 2-3 times daily as needed.
2-3 times daily as needed
As needed for symptomatic relief; no strict duration limit for external use
External use may be acceptable for children over 6 under practitioner guidance.
External application of wormwood avoids systemic thujone exposure and is therefore considerably safer than internal use. Traditional applications include: compresses for arthritic and rheumatic joint pain, bruise and sprain poultices, wound washes (antimicrobial), and rubbing with wormwood-infused oil for muscular aches. The counter-irritant properties of the volatile oil provide warming, circulation-enhancing effects at the application site. Skin sensitivity reactions are possible; test on a small area first. Avoid application to broken skin or mucous membranes.
Safety & Interactions
Class 2c
Not to be used with specific medications (AHPA Botanical Safety Handbook)
Contraindications
ABSOLUTE contraindication. Wormwood is a recognized emmenagogue with a historical reputation as an abortifacient. Thujone and other volatile oil components may stimulate uterine smooth muscle contraction, potentially causing miscarriage. The German Commission E, ESCOP, AHPA, and all major herbal safety authorities list pregnancy as an absolute contraindication. No dose of wormwood should be taken during pregnancy or when pregnancy is suspected. This is classified as AHPA Class 2b (not to be used during pregnancy).
Wormwood should be avoided during breastfeeding. Thujone and other volatile oil components are lipophilic and may be transferred to breast milk, potentially exposing the nursing infant to neurotoxic thujone. The intensely bitter compounds may also taint the flavor of breast milk and reduce infant acceptance. AHPA Class 2c (not to be used while nursing). Insufficient safety data on lactation exposure.
Thujone is a GABA-A receptor antagonist that lowers the seizure threshold. In patients with epilepsy or other seizure disorders, thujone-containing preparations could potentially trigger seizures or counteract the effects of anticonvulsant medications. This is a serious neurological safety concern that constitutes an absolute contraindication. Patients with a personal or family history of seizure disorders should not use wormwood.
The potent gastric acid-stimulating action of wormwood's bitter principles would exacerbate active peptic ulcer disease by increasing acid exposure on the ulcerated mucosa. Commission E specifically lists gastric and intestinal ulcer as a contraindication. This restriction applies to active ulceration; patients with healed ulcers on maintenance therapy should use wormwood only with caution and medical supervision.
Wormwood is a member of the Asteraceae family. Patients with documented allergies to other Asteraceae plants (ragweed, chrysanthemum, chamomile, echinacea, arnica, marigold, etc.) may be at increased risk of allergic reactions to wormwood due to cross-reactive sesquiterpene lactone sensitization. Sesquiterpene lactones (including absinthin) are the primary contact allergens in Asteraceae plants. Allergic contact dermatitis and, rarely, systemic allergic reactions are possible.
The cholagogue action of wormwood (stimulating gallbladder contraction) could precipitate biliary colic or acute cholecystitis in patients with impacted gallstones. Patients with known gallstones should use wormwood only under medical supervision and with imaging confirmation that stones are not obstructing the biliary tract.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Phenobarbital, phenytoin, carbamazepine, valproic acid, and other anticonvulsants (Anticonvulsant/antiepileptic medications) | moderate | Thujone is a GABA-A receptor antagonist that lowers the seizure threshold by blocking inhibitory GABAergic neurotransmission. This mechanism directly opposes the anticonvulsant effects of drugs that enhance GABAergic function (phenobarbital, benzodiazepines, valproic acid) or reduce neuronal excitability by other mechanisms (phenytoin, carbamazepine). Concurrent use could reduce anticonvulsant efficacy and increase seizure risk. |
| Warfarin, heparin, and other anticoagulants (Anticoagulants) | theoretical | Some in vitro evidence suggests wormwood constituents may affect platelet function or coagulation parameters. The mechanism is not well characterized but may involve flavonoid effects on platelet aggregation or potential CYP450 interactions affecting warfarin metabolism. The interaction is theoretical and based on limited evidence. |
| Proton pump inhibitors (omeprazole, lansoprazole, etc.) and H2 receptor antagonists (ranitidine, famotidine) (Acid-suppressing medications) | minor | Pharmacological antagonism: wormwood stimulates gastric acid secretion through the bitter reflex, while PPIs and H2 blockers suppress gastric acid. Concurrent use may reduce the efficacy of either treatment -- the bitter tonic effect of wormwood may be blunted by acid suppression, and the acid-stimulating effect of wormwood may partially counteract acid-suppressive therapy. |
| Benzodiazepines (diazepam, lorazepam, alprazolam, etc.) and other GABAergic drugs (Sedatives/anxiolytics) | moderate | Thujone's GABA-A receptor antagonism may reduce the sedative, anxiolytic, and muscle-relaxant effects of benzodiazepines and other drugs that act by enhancing GABAergic neurotransmission. The interaction is at the receptor level: thujone blocks the chloride channel that benzodiazepines potentiate. |
| CYP2D6 and CYP3A4 substrates (Various (medications metabolized by these cytochrome P450 enzymes)) | theoretical | In vitro studies have suggested that some Artemisia absinthium constituents (particularly flavonoids such as artemetin) may inhibit CYP2D6 and CYP3A4 enzyme activity. If clinically relevant, this could increase serum levels of drugs metabolized by these enzymes. However, the in vitro concentrations used may not be achievable in vivo at standard herbal doses. |
Pregnancy & Lactation
Pregnancy
unsafe
Lactation
unsafe
ABSOLUTELY CONTRAINDICATED in pregnancy and lactation. Wormwood is classified as AHPA Class 2b (not to be used during pregnancy) and 2c (not to be used while nursing). The emmenagogue and potential abortifacient activity is well documented in traditional literature and supported by the presence of uterine-stimulant volatile oil components. Thujone is lipophilic and may cross the placental barrier and enter breast milk, posing a neurotoxicity risk to the fetus and nursing infant. There are no circumstances under which wormwood should be used during pregnancy or breastfeeding. Historical use of wormwood as an abortifacient in folk practice resulted in significant morbidity and mortality and is categorically condemned in modern herbal practice.
Adverse Effects
References
Monograph Sources
- [1] Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS (eds). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines -- Wormwood (Absinthii herba). American Botanical Council / Integrative Medicine Communications, Austin/Boston (1998)
- [2] ESCOP (European Scientific Cooperative on Phytotherapy). ESCOP Monographs: Absinthii herba (Wormwood). ESCOP Monographs, 2nd edition, Thieme, Stuttgart (2003)
- [3] Wichtl M (ed), translated by Bisset NG, Wichtl M. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis -- Absinthii herba. Medpharm Scientific Publishers / CRC Press, Stuttgart/Boca Raton (2004)
- [4] Blumenthal M, Goldberg A, Brinckmann J (eds). Herbal Medicine: Expanded Commission E Monographs -- Wormwood herb. American Botanical Council / Integrative Medicine Communications, Austin/Newton (2000)
- [5] Mills S, Bone K. Principles and Practice of Phytotherapy: Modern Herbal Medicine -- Artemisia absinthium. Churchill Livingstone / Elsevier, Edinburgh (2000)
- [6] Gardner Z, McGuffin M (eds). American Herbal Products Association's Botanical Safety Handbook, 2nd edition -- Artemisia absinthium. CRC Press / American Herbal Products Association, Boca Raton (2013)
Clinical Studies
- [7] Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: A double-blind placebo-controlled study on 40 patients. Phytomedicine (2007) ; 14 : 87-95 . DOI: 10.1016/j.phymed.2007.01.001 . PMID: 17240130
- [8] Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease -- A controlled clinical trial. Phytomedicine (2010) ; 17 : 305-309 . DOI: 10.1016/j.phymed.2009.10.013 . PMID: 19962291
Traditional Texts
- [9] Anonymous (ancient Egyptian physicians). Ebers Papyrus (Papyrus Ebers). Original text ca. 1550 BCE; multiple modern translations. Leipzig University Library collection. (-1550)
- [10] Pedanius Dioscorides. De Materia Medica (Peri hyles iatrikes). Original text ca. 70 CE; multiple modern translations including Gunther (1934) and Beck (2005) (70)
Pharmacopeias & Reviews
- [11] Council of Europe, European Directorate for the Quality of Medicines. European Pharmacopoeia, 10th edition -- Absinthii herba (Wormwood). EDQM, Strasbourg (2020)
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.